Item 7.01 Regulation FD Disclosure.

On January 4, 2023, ImmunoGen, Inc. issued a press release announcing the appointment of Michael J. Vasconcelles, M.D. as Executive Vice President, Research, Development, and Medical Affairs. A copy of this press release is attached as Exhibit 99.1.

The information contained in this item, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits

Exhibit
  No.              Description

 99.1       Press release of ImmunoGen,
          Inc. dated January 4, 2023

  104     Cover Page Interactive Data
          File (embedded within the
          Inline XBRL (eXtensible
          Business Reporting Language)
          document)

© Edgar Online, source Glimpses